Status:
COMPLETED
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
German Adjuvant Breast Cancer Group
Conditions:
Breast Cancer
Eligibility:
FEMALE
Up to 75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and tolerability of 3 years treatment with anastrozole after a prior 2 years' treatment with tamoxifen versus 5 years treatment with tamoxifen in...
Eligibility Criteria
Inclusion
- Signed informed consent,
- Post-menopausal women ≤75 years,
- histologically confirmed invasive breast carcinoma (no distant metastases),
- positive hormone receptor status,
- continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery
Exclusion
- menopause status maintained by medication,
- pre-operative chemotherapy or hormone therapy or radiation therapy,
- relapse or second carcinoma or previous cancerous disease,
- breast carcinoma in situ,
- simultaneous carcinoma of the opposite side or secondary breast,
- 10 or more tumour-infiltrated lymph nodes.
- serious accompanying diseases
Key Trial Info
Start Date :
November 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2004
Estimated Enrollment :
1059 Patients enrolled
Trial Details
Trial ID
NCT00287534
Start Date
November 1 1996
End Date
September 1 2004
Last Update
June 9 2009
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Albstadt, Germany
2
Research Site
Berlin, Germany
3
Research Site
Cloppenburg, Germany
4
Research Site
Eggenfelden, Germany